PBH vs HCM
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
PBH · Prestige Consumer Healthcare$42.98 ▼ 3.02%
HCM · Hutchmed (China)$15.16 ▲ 6.76%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- PBH -28.9%
- HCM +0.5%
Head to head
| Metric | PBH | HCM |
|---|---|---|
| Price | $42.98 | $15.16 |
| Change today | ▼ 3.02% | ▲ 6.76% |
| Market cap | $2.04B | $2.64B |
| Return, 3 months | -18.9% | +20.8% |
| Return, year to date | -30.3% | +13.7% |
| Return, 1 year | -28.3% | +1.4% |
| P/E (TTM) | 13.3 | 189.5 |
| P/B | 1.0 | 2.1 |
| P/E percentile vs own 5y | 33rd | 97th |
| Dividend yield | – | – |
| Revenue growth (YoY, latest qtr) | +6.5% | +37.3% |
| Net profit growth (YoY) | -38.5% | -81.3% |
| Gross margin | 53.5% | 41.6% |
| Operating margin | 26.3% | -5.7% |
| Net margin | 15.6% | 3.3% |
| Return on equity | 9.1% | 1.4% |
| Analyst target vs. price | +67.5% | +20.4% |
| Analyst buy share | 100% | 100% |
| RSI (14) | 37 | 63 |
| 30-day volatility | 64.0% | 44.6% |
| Max drawdown, 1 year | -38.8% | -37.8% |
| Trend read | Strong downtrend | Strong uptrend |
| Analyst consensus | Buy | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- HCM is the largest of the group by market value.
- HCM has returned the most over the past year.
- PBH carries the lowest trailing P/E.
- HCM is growing revenue fastest.
- PBH keeps the most profit per dollar of sales.
- HCM has been the calmest stock over the last 30 days.